LOGIN  |  REGISTER

List of Diagnostics & Research Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 580.37
1.00 0.17
268,423
381.31M
US$ 221.300B
US$ 250.57
1.80 0.72
636,211
739.70M
US$ 185.350B
US$ 139.76
0.28 0.20
668,124
385.52M
US$ 53.880B
US$ 252.36
-0.22 -0.09
168,359
182.01M
US$ 45.930B
US$ 542.50
2.93 0.54
60,243
83.09M
US$ 45.080B
US$ 146.58
-0.80 -0.54
397,798
293.06M
US$ 42.960B
US$ 1.00
-3.64 -0.27
16,577
21.39M
US$ 28.500B
US$ 334.76
5.26 1.60
126,795
82.50M
US$ 27.620B
US$ 138.39
-0.29 -0.21
343,651
158.90M
US$ 21.990B
US$ 344.76
-0.43 -0.12
54,076
59.20M
US$ 20.410B
US$ 217.74
1.17 0.54
148,029
84.10M
US$ 18.310B
US$ 132.46
1.40 1.07
185,493
110.71M
US$ 14.660B
US$ 271.14
1.77 0.66
165,699
51.35M
US$ 13.920B
US$ 105.71
0.30 0.28
167,276
123.52M
US$ 13.060B
US$ 69.98
3.10 4.64
2.28M
181.53M
US$ 12.700B
US$ 404.28
1.01 0.25
38,851
30.76M
US$ 12.440B
US$ 92.16
1.70 1.88
259,572
120.76M
US$ 11.130B
US$ 42.79
0.04 0.09
561,708
221.36M
US$ 9.470B
US$ 61.95
1.49 2.46
238,738
68.55M
US$ 4.250B
US$ 48.81
0.31 0.64
135,049
73.71M
US$ 3.600B
US$ 15.65
0.18 1.16
343,879
216.52M
US$ 3.390B
US$ 12.00
0.13 1.10
497,134
282.83M
US$ 3.390B
US$ 48.77
0.51 1.06
147,978
66.85M
US$ 3.260B
US$ 23.49
-0.11 -0.47
57,023
124.34M
US$ 2.920B
US$ 19.70
1.74 9.69
2.46M
121.71M
US$ 2.400B
US$ 34.77
0.29 0.84
466,973
57.82M
US$ 2.010B
US$ 15.67
0.47 3.09
140,542
127.61M
US$ 2.000B
US$ 21.53
0.13 0.61
140,849
89.87M
US$ 1.930B
US$ 3.81
0.09 2.28
2.42M
267.95M
US$ 1.020B
US$ 39.58
0.18 0.46
16,041
23.85M
US$ 943.980M
US$ 1.20
0.13 11.68
13.33M
696.99M
US$ 832.900M
US$ 2.74
0.05 1.67
410,555
290.12M
US$ 793.480M
US$ 22.07
0.38 1.75
44,359
29.78M
US$ 657.240M
US$ 22.35
1.06 4.98
55,305
27.45M
US$ 613.370M
US$ 10.96
0.44 4.18
197,729
51.78M
US$ 567.510M
US$ 9.06
-0.40 -4.23
123,961
31.46M
US$ 285.030M
US$ 10.83
0.18 1.69
165,006
25.79M
US$ 279.310M
US$ 1.93
0.04 2.17
174,246
121.83M
US$ 235.270M
US$ 0.54
0.03 5.31
1.89M
315.44M
US$ 169.550M
US$ 4.78
-0.03 -0.52
23,777
29.76M
US$ 142.100M
US$ 1.45
0.0099 0.69
7,017
96.94M
US$ 140.550M
C$ 0.46
-0.01 -2.13
30,500
278.58M
C$ 128.150M
US$ 4.03
0.005 0.12
4,173
31.62M
US$ 127.270M
US$ 1.96
-0.02 -1.01
11,343
38.21M
US$ 74.890M
US$ 2.72
0.26 10.57
214,594
27.29M
US$ 74.230M
US$ 0.71
0.01 1.43
1,081
102.68M
US$ 72.900M
US$ 1.28
0.01 0.79
27,946
51.23M
US$ 65.570M
US$ 1.16
0.07 6.43
904,750
54.69M
US$ 63.450M
US$ 0.78
0.03 4.31
131,935
78.69M
US$ 60.980M
US$ 2.22
0.00 0.00
19,405
26.33M
US$ 58.450M
C$ 0.50
0.00 0.00
0
109.27M
C$ 54.640M
US$ 1.53
0.01 0.66
108,058
27.79M
US$ 42.520M
US$ 1.13
0.02 1.80
19,324
31.26M
US$ 35.320M
US$ 3.38
-0.05 -1.46
7,698
10.34M
US$ 34.950M
C$ 0.30
0.00 0.00
0
90.89M
C$ 27.270M
US$ 1.57
0.01 0.64
18,239
17.24M
US$ 27.070M
US$ 0.69
-0.02 -2.67
30,240
34.62M
US$ 23.890M
US$ 2.02
-0.06 -2.96
30,250
11.13M
US$ 22.460M
US$ 1.03
0.02 1.49
46,754
21.30M
US$ 21.830M
US$ 1.03
0.04 4.03
15,766
20.36M
US$ 20.970M
US$ 0.70
0.0063 0.91
17,762
27.87M
US$ 19.410M
US$ 2.95
0.20 7.27
170,427
5.85M
US$ 17.260M
US$ 2.93
-0.07 -2.33
3,465
5.80M
US$ 16.990M
US$ 3.00
-0.05 -1.64
256,594
4.93M
US$ 14.790M
C$ 0.13
0.00 0.00
0
99.64M
C$ 12.460M
US$ 2.88
0.07 2.49
8,428
3.85M
US$ 11.090M
US$ 1.05
0.04 3.86
26,537
10.04M
US$ 10.530M
US$ 6.01
-0.19 -3.06
2,363
1.42M
US$ 8.530M
US$ 0.73
-0.10 -11.62
242,108
11.04M
US$ 8.000M
C$ 0.11
-0.01 -8.33
19,000
71.31M
C$ 7.840M
C$ 0.08
0.00 0.00
0
94.47M
C$ 7.560M
US$ 0.43
-0.002 -0.47
17,777
16.98M
US$ 7.230M
US$ 0.68
-0.04 -5.56
676,069
10.01M
US$ 6.780M
C$ 0.12
0.00 0.00
14,500
54.90M
C$ 6.590M
C$ 0.05
-0.005 -9.09
136,000
122.72M
C$ 6.140M
US$ 0.02
0.00 0.00
0
286.49M
US$ 5.590M
US$ 0.02
0.00 0.00
0
161.02M
US$ 2.580M
US$ 0.24
-0.02 -6.37
58,431
9.09M
US$ 2.140M
US$ 0.42
0.0039 0.94
32,477
5.03M
US$ 2.110M
C$ 0.01
0.00 0.00
0
160.81M
C$ 1.610M
US$ 3.65
0.08 2.24
43,311
-
US$ -

Latest News From Diagnostics & Research Stocks


T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient

LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2025. The products covered under the contract with Vizient include the T2Dx®... Read more


Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations

SOUTH SAN FRANCISCO, Calif. / Mar 28, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel developed to enable researchers to detect a more complete view of genetic variation during whole exome sequencing (WES). “No one single human genome can serve... Read more


Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI, March 28, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to... Read more


Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early MADISON, Wis. / Mar 28, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard® Esophagus test... Read more


DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results

Full-year 2023 revenue of $20.4 million reflects a decrease from 2022 revenue of $7.3 due to a managed decrease in B2C and strategic milestone revenue as the core B2B2C revenue increased. 2023 B2B2C, employers and health plans recurring revenues increased 39% year over year as the core business continues to gain traction. Commercial revenues in 2023 generated majority of the revenue with B2B2C growing from 13% to 25% of total revenue from 2022 to 2023. GAAP operating... Read more


Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results

2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter and full-year 2023 to $3.5 million and $15.9 million, respectively Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical... Read more


Psychemedics Reports 2023 Financial Results

DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023. “2023 proved to be another challenging year due to the negative impact of major economic forces. The labor shortage continues and remains unprecedented in its severity and duration, having an adverse impact on our clients. Despite these challenges,... Read more


NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting

Insights from 11 Abstracts Highlight Key Findings Across the Oncology Care Spectrum FT. MYERS, Fla. / Mar 27, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, alongside research collaborators, will present key findings from 11 abstracts at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5-10 (booth #915), demonstrating its commitment to advancing cancer patient care through... Read more


Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes

HiFi Data Generated on the Revio™ System will Support the EU and Estonian Government-Funded Center for Personalized Medicine and Unlock Discoveries Across Cardiology, Mental and Reproductive Health, Drug Response, Cancer Research and Rare Diseases MENLO PARK, Calif., March 27, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the University of Tartu, host of Estonia's... Read more


Castle Biosciences Announces Updates to its Board of Directors

FRIENDSWOOD, Texas / Mar 27, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Rodney Cotton has been appointed to its board of directors, effective immediately, and will stand for election at Castle’s 2024 Annual Meeting of Stockholders, expected to be held in May 2024. The Company further announced that Mara G. Aspinall will not stand for re-election to its... Read more


Genetic Technologies Global Collaborations and Innovation Update

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation. This innovation is driven by: Strong global academic relationships with research groups Continuous development of the geneType portfolio A deep pipeline of new unique and... Read more


Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease

Findings suggest the test can reduce the need for PET imaging in some patients with mild cognitive decline to enable therapeutic focus on non-Alzheimer's disease causes, broadening access to quality evaluation and lowering healthcare costs SECAUCUS, N.J., March 26, 2024 /PRNewswire/ -- A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer's disease (AD) is likely not the cause of patients'... Read more


QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system

Venlo, the Netherlands, March 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of the QIAstat-Dx Analyzer 2.0, including the Software 1.6 upgrade, a significant enhancement to the widely-used QIAstat-Dx Analyzer 1.0 for reliable, fast and cost-effective diagnosis of complex syndromes. The upgraded diagnostic system, powered by the new QIAstat-Dx Operational Module PRO with a 64‑bit processor and 4GB of RAM, introduces... Read more


Neuronetics: NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression

MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar Advanced Therapy for use as an adjunct for the treatment of major depressive disorder (MDD) in adolescent patients aged 15-21. NeuroStar... Read more


Genetic Technologies to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to announce the development of the Company’s most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test. GeneType's latest innovation will... Read more


Olink reports fourth quarter and full year 2023 financial results

UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023. Highlights Fourth quarter 2023 revenue totaled $68.6 million, representing year over year growth of 18% on a reported basis and 17% on a constant currency adjusted like-for-like basis Full year revenue 2023 revenue totaled $169.6 million, achieving year over year... Read more


Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

LOUISVILLE, Colo. / Mar 25, 2024 / Business Wire / Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer. Biodesix will utilize its array of genomics, proteomics,... Read more


VolitionRx Announces Full Fiscal Year 2023 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., March 25, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the full fiscal year ended December 31, 2023. Volition management will host a conference call tomorrow, March 26 at 8:30 a.m. U.S. Eastern Time... Read more


Justera Health Appoints Tyler Burpee to Board of Directors

Toronto, Ontario--(Newsfile Corp. - March 22, 2024) - Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) ("Justera" or the "Company") announces the appointment of Tyler Burpee to the board of directors and the resignation of director Ian Kim for personal reasons, effective March 21st, 2024. The Company extends its deepest appreciation to Mr. Kim for his service and contributions since his appointment to the board of directors on December 6, 2023. Mr. Burpee is a seasoned... Read more


Castle Biosciences: Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the...

Castle’s second presentation at SSO 2024 shows that in a study of 979 patients, DecisionDx-Melanoma demonstrated clinical use value in patients with TI cutaneous melanoma (CM), identifying high-risk patients who could consider a more intensive treatment pathway, such as a sentinel lymph node biopsy (SLNB) and imaging surveillance FRIENDSWOOD, Texas / Mar 22, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative... Read more


Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.  U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary... Read more


Aspira Women’s Health to Present at the MedInvest Biotech & Pharma Investor Conference

AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference taking place in New York City on April 3-4, 2024. Management will be available for one-on-one meetings with... Read more


Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors

BRANFORD, Conn. / Mar 21, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation... Read more


Sera Prognostics Reports Fourth Quarter 2023 Financial Results

SALT LAKE CITY, March 20, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights: Announced that the Data Safety Monitoring Board (DSMB) overseeing Sera's pivotal Prematurity Risk Assessment Combined... Read more


Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination. U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap® products... Read more


VolitionRx and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan

HENDERSON, Nev. , March 20, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems"), a leading veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan. Volition's supply agreement enables Fujifilm Vet Systems to sell and perform cancer screening services for dogs using the... Read more


23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 ‘1473 also induces Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhanced effector function SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed... Read more


Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care  BURLINGTON, N.C., March 20, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch and immediate availability of its test to identify the presence or absence of phosphorylated tau 217 (pTau217), a pivotal blood biomarker designed to aid in the... Read more


HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results

First Patients Enrolled in Pivotal Study Evaluating AIMIGo™ System for Synthesizing a 12-Lead ECG Ongoing Clinical and Regulatory Progress for the AIMIGo 3D VECG System Recently Received 2 New Patents for our Proprietary Technologies Management to Host Webcast and Conference Call Today At 4:30 p.m. ET SANTA CLARA, Calif. / Mar 20, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the... Read more


Bionano Genomics Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer (HBOC) syndrome showing that when tumors exhibited higher overall numbers of structural variations (SVs) they tended to have more mutated genes and altered signaling pathways, which may correlate with poor prognosis, tumor progression and chemotherapy resistance. Researchers... Read more


Castle Biosciences: Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant...

The consensus guidelines were drafted by a multidisciplinary panel of radiation oncologists and dermatologists/Mohs micrographic surgeons with expertise in cutaneous squamous cell carcinoma (SCC) management; they provide a recommended framework for using DecisionDx-SCC testing with American Joint Committee on Cancer 8th Edition (AJCC8) staging to guide decisions regarding the use of adjuvant radiation therapy (ART) in patients with high-risk SCC to control disease prog... Read more


Centogene Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the extension of an ongoing partnership with Takeda (TSE: 4502/NYSE: TAK) to diagnose patients with Lysosomal Storage... Read more


Volition appoints Dr Andrew Retter as Chief Medical Officer

HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024. Dr Retter will provide medical leadership at Volition and ensure the company's scientific and clinical efforts are aligned with patient needs. Andrew is an Intensive Care Consultant at Guy's and St. Thomas' NHS Foundation Trust in London, where... Read more


Co-Diagnostics CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, England

SALT LAKE CITY, Utah, March 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Dx CEO Dwight Egan will deliver the keynote address at the 5th Annual Infectious Disease Diagnostics and Molecular Diagnostics Conference, organized by MarketsandMarkets and held March 21-22, 2024, in London, En... Read more


Applied DNA Sciences Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start

Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods  Project Slated for Completion Coincident with Company's Planned Initiation of GMP Manufacturing for Linea™ DNA IVT Templates  STONY BROOK, NY and JUPITER, FL / ACCESSWIRE / March 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company (MRVI) and global... Read more


T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel

LEXINGTON, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the publication of a new study highlighting the clinical benefits and performance of real-world use of the T2Resistance® Panel in The Journal of Clinical Microbiology. The European study demonstrated high accuracy for the T2Resistance Panel, faster detection... Read more


Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024. Designed for pharmacists, physicians, and healthcare professionals,... Read more


Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer

AUSTIN, Texas / Mar 18, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a randomized, multicenter, prospective phase III clinical trial in France investigating molecular residual disease (MRD)-guided adjuvant treatment in stage II colorectal cancer (CRC) patients. The study’s... Read more


Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Next-generation suite enhances research productivity and innovation across chemical, pharmaceutical, and biotechnology industries and academia Seamless integration within Revvity Signals Research platform empowers multidisciplinary discoveries WALTHAM, Mass. / Mar 18, 2024 / Business Wire / Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals Software, is introducing the new Signals ChemDraw® offering, the latest... Read more


BioNxt Solutions Reports Commercialization of ODF Cladribine Product for MS Next Steps

VANCOUVER, BC / ACCESSWIRE / March 18, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that based on the recent success of its toxicity and comparative pharmacokinetic ("PK") studies the Company is advancing towards human comparative bioavailability studies on an expedited basis. The next steps in the development and commercialization process include technology and process transfer, upscaling of manufacturing... Read more


Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President

Dr. Milligan brings a wealth of experience across critical business functions and deep relationships with leaders throughout the healthcare and pharmaceutical sectors Aspira also announces Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team following the departure of Dr. Jody Berry AUSTIN, Texas, March 18, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH),... Read more


Exagen Reports Strong Fourth Quarter and Full-Year 2023 Results

CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: Record total revenue of $52.5 million for the full-year 2023, and total revenue of $13.8 million for the fourth quarter of 2023. Record 137,650 AVISE® CTD tests performed for the full-year 2023, including 30,438 tests... Read more


Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Initiated limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systems The Company is engaged in the process to seek strategic partnerships aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value Recent exercise of certain outstanding warrants provided infusion of $2.7M in gross proceeds to the Company, which extended its cash runway into... Read more


Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice BURLINGTON, N.C., March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with... Read more


New Study Shows that Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for...

Study data show that one-third of the IDgenetix-guided medication recommendations were due to drug-drug interactions and lifestyle factors, demonstrating the value of this additional information in guiding selection of neuropsychiatric medications for older adults in cohort of patients 65 and older, with majority being on five or more medications at the time of testing FRIENDSWOOD, Texas / Mar 15, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company... Read more


Applied DNA Sciences to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress

STONY BROOK, NY / ACCESSWIRE / March 14, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will showcase its Linea™ IVT and Linea™ DNA platforms at the 24th Annual World Vaccine Congress, which will be held April 1 - 4, 2024. Applied DNA sales team members will be available during the Congress for one-on-one meetings. Location:      Walter E. Washington Convention Center, Washington,... Read more


First Patients Enrolled in Pivotal Study Evaluating HeartBeam’s AIMIGo™ System for Synthesizing a 12-Lead ECG

VALID-ECG Study will Form the Basis of the Company’s Upcoming FDA 510(k) Submission SANTA CLARA, Calif. / Mar 14, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has enrolled the first patients in the VALID-ECG (Clinical Validation of the AIMIGo 12-Lead ECG Synthesis Software for Arrhythmia Detection) pivotal study. The first... Read more


Charles River Laboratories and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration

Next-generation AAV gene therapy to target debilitating pain disorders WILMINGTON, Mass. / Mar 14, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics, Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to established contract development... Read more


Waters Streamlines and Expedites PFAS Testing with Innovative Oasis Dual-Phase Cartridges

News Summary: Waters Oasis™ Dual-phase PFAS Analysis Cartridges simplify sample preparation for EPA 1633 testing for analysis of PFAS concentrations in non-potable water, soils, biosolids, and tissue. Reduces sample preparation time by 20% and sample processing time by approximately 30 minutes per batch to boost sample throughput and help busy laboratories save time and money. Cartridge lots are QC-tested by an accredited laboratory for low residual PFAS to help... Read more


Co-Diagnostics Reports Full Year 2023 Financial Results

SALT LAKE CITY, March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023. Full Year 2023 Financial Results: Revenue of $6.8 million, down from $34.2 million during the prior year primarily due to the decline in global demand for the Logix Smart® COVID-19 tests.... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB